The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
When you say something cooking behind the scenes. Good or bad?
Something definately cooking behind the scenes. MMS will take 500k... Today options RNS... Added a few more today while its been quite :-)
They will take 500k+ shares, 5 x the normal so something brewing for sure ! Thats on a very quiet time on AIM !
Agree with rightback. Options before a rise i would say .
Good luck everyone.
Exactly this ! We all know how these things work !
Share price almost 50% down over last 12 months.
Options available at about 10% more than current share price.
Not really incentivising employees - more like rewarding failure!
Good news coming soon then.
RNS Share options @ 4.38p
He is ok, and still holds all his shares....
I think riddler has got weary of banging on the drum here. I seem to recall though that someone said here he wasn't too good healthwise at the moment so perhaps combination of the 2. But not too sure
Riddler these days ?
Hi Investor, read the article - can't say I understood it all though!! The Virtual Tumor product is protected by both patents and is also trade marked. We do seem to have a unique offering in an exponential growth area that has only started to become a practical reality in the last decade or so.
I don't think that PYC's potential is actually appreciated by the current MC. You would think that to work with much bigger pharma companies over several years demonstrates our unique advantage. Got a feeling that PYC's time is about to come.
PYC are helping Merck :-)
Wish someone would put takeover bid of this company at 10p per share and put us all out of this agonising misery of up down up down and no real forward momentum. No doubt I will get lambasted by some for this post but the b o d have had years to reward shareholders but in truth nothing is happening.
Black rock generate 22 billion in revenue per year and have a MC of 100 billion and have a great knowledge and background in this field which massive scope to expand
A 13D filing on Thursday disclosed a letter of intent that a portfolio company of BlackRock (NYSE: BLK) intends to make a proposal to transact with certain non-core assets of Tabula Rasa Healthcare (Nasdaq: TRHC).
Why it matters: Axios reported in late March that Tabula Rasa, working with Citigroup, was in advanced discussions regarding the sale of non-core assets, including PrescribeWellness.
Sources said then that conversations were being held with PE-backed strategics, with BlackRock-backed Transaction Data Systems among logical buyers of PrescribeWellness. TDS is a pharmacy technology company.
PrescribeWellness is a CRM (customer relationship management) tool that’s integrated with over 10,000 independent pharmacy operating systems.
State of play: Besides PE-backed portfolio companies, logical buyers would include Omnicell (NASDAQ: OMNCL), should it want to beef up its pharmacy-focused hardware and software presence within independent pharmacies.
Flashback: BlackRock’s perpetual capital fund agreed to acquire a majority interest in Transaction Data Systems in May 2021, with minority investor GTCR retaining a minority interest.
Context: Tabula Rasa has been outspoken about its plans to unload non-core assets to boost profitability, strengthen the balance sheet and become and remain cash flow positive by Q3.
The company in February disclosed letter of intent to sell DoseMeRx, a precision dosing tool used by pharmacists and physicians
Tabula Rasa bought PrescribeWellness less than three years ago for $150 million, but current price talk could not be determined.
BlackRock declined to comment, while Tabula Rasa did not immediately return a request for comment.
Biopharma giant Sanofi is setting its sights on AI for drug discovery, inking a deal worth more than $100 million with tech company Exscientia.
As part of the deal, Exscientia is eligible for as much as $5.2 billion in payments for clinical development, regulatory and commercial milestones.
85,932 shares for me.. Showing as a sell
In its 2018 program of work with Merck, Physiomics believes it has developed genuinely ground-breaking predictive models that will add significant value to drug development programmes. The two companies have provisionally agreed that they will aim to publish selected elements of their work at one or more major conferences in 2019. Dr Jim Millen, CEO of Physiomics, said: "We are now entering the eighth year of our relationship with Merck, during which time we have provided a range of pre-clinical and clinical predictive modelling services using our Virtual Tumour technology. We remain immensely proud to be working with one of the world's foremost pharmaceutical companies, in an area as important and rapidly growing as oncology. We look forward to this collaboration continuing."
"Merck will be big news for PYC..."
Is a post from 8 Apr '18 on this board. People should go dig the archive to see what people have been saying and what's actually materialised here.
Merck KGaA is a major player. It is perhaps testament to our product that PYC has been a consistent customer/client for many years and Virtual Tumor has attracted increased their spending with us over those years. In the December RNS Millen said that we were engaged with them on a number of their key clinical programs. Apparently this area is being seen as increasingly important in general to PYC. See the 10th of May Trading update. PYC is looking to move from pre-clinical work to more high value clinical projects. Couple this with the commercial partnership/business projects and growth looks good.
It seems to me then that this relationship will run and run and be increasingly valuable. Not only that but with other business contracts now being named (which wasn't always the case) our credence is growing and so is our revenue. Good times coming I think. Finally I'm really looking forward to reading the year end trading update - hopefully in July.
"Key partner" what a load of rubbish. They're a tiny contractor for Merck.
More Merck deals coming As per Dec 2021 RNS
Merck have annualy increased their business with PYC and we are now a key partner for them as prove by the Dec 2021 RNS